MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.7 USD | +3.42% |
|
+6.96% | +12.35% |
| 03:02pm | Moderna Signs Nonexclusive License Deal in Japan for COVID-19-related Intellectual Property | MT |
| Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
Presenter SpeechLavina Talukdar (Executives)Good morning, and welcome to Moderna's Third Annua...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
108
USD
Average target price
134.3
USD
Spread / Average Target
+24.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.27% | 41.34B | |
| +2.16% | 42.75B | |
| +47.70% | 41.61B | |
| -8.83% | 26.59B | |
| +6.50% | 25.49B | |
| -22.97% | 18.12B | |
| +30.28% | 12.24B | |
| -2.03% | 11.76B | |
| +8.72% | 11B | |
| -15.84% | 10.07B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Transcript : Moderna, Inc. - Special Call
